Population study of the gastrointestinal stromal tumors based on the data from the clinical registry - Czech and Slovak Republic

Konference: 2013 38th Congress ESMO a 17th Congress ECCO - 32nd ESTRO-účast ČR

Kategorie: Sarcom

Téma: Sarcoma: Soft Tissue and Bone

Číslo abstraktu: 3821

Autoři: MUDr. Beatrix Bencsiková; MUDr. Andrea Jurečková; MUDr. Ilona Kocáková, Ph.D.; Mgr. Jana Strenková; Ing. Petr Brabec; Mgr. Zbyněk Bortlíček; prof. MUDr. Rostislav Vyzula, CSc.

Background: Gastrointestinal stromal tumors (GIST) are quite rare mesenchymal tumors mostly presenting typical expression of thyrosinkinase receptor c-Kit (CD117). In the past years, especially before 2001, there have been problems with identification and understanding of GIST and therefore a lack of significant population data and clinical studies focusing on patients with these uncommon malignancies.

Material and Methods: The online registry called ‘reGISTer’ has been compiled and maintained since December 2006. It involves relevant epidemiological data, pathology results and molecular analysis, clinical information and treatment results on patients with GIST from the Czech and Slovak Republic. Until November 2012 there have been included adequate dataset on 845 patients.

Results: Most of the tumors belong to the high-risk group (50.4%, n=426), most common location is jejunum and stomach. More than 70% of the tumors are resectable at the time of diagnosis. Median overall survival is 9.2 years. In cases of inoperable and metastatic disease targeted therapy is used, ie. imatinib mesylate in the first line, sunitinib in the second line or regorafenib in the third line.

Table: Results of treatment with imatinib in the palliative setting (n=399 patients)
Overall survival  
All 65.2 months
Non-metastatic/non-resectable at beginning of treatment 80.3 months
Metastatic at the beginning of treatment 63.3 months
Progression free survival  
All 32.3 months
Non-metastatic/non-resectable at beginning of treatment 43.0 months
Metastatic at beginning of treatment 28.1 months
2-year survival – all 82.2%
Median treatment length 20.1 months
Best treatment response (CR+PR+SD*) 82.6%
 

*CR: complete response; PR: partial response; SD: stable disease.

Conclusions: The poster comprises up-to-date analysis of the register. Presented data are generally similar to those from the world-wide clinical studies published recently.

Acknowledgments: Authors thank all centers participating in the reGISTer project both in the Czech and Slovak Republic.

No conflict of interest.

Keywords:
gastrointestinal stromal tumor
Clinical registry
imatinib,sunitinib,regorafenib

web

Datum přednesení příspěvku: 27. 9. 2013